文献速递淋巴瘤

ATR抑制剂elimusertib展现抗淋巴瘤活性并与PI3K抑制剂copanlisib协同作用

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
PubMed 文献 · Br J Haematol · 2023-11-27

本研究在大量淋巴瘤细胞系中表征ATR抑制剂elimusertib(BAY 1895344)的活性,并在体外和体内评估其与临床已批准的PI3K抑制剂copanlisib联用的效果。Elimusertib在多种淋巴瘤亚型中表现出强效抗肿瘤活性,与复制应激、细胞周期调控相关基因表达及CDKN2A缺失相关;在多个肿瘤模型中,其抗肿瘤活性强于另一种ATR抑制剂ceralasertib,且该活性在DDR功能正常和缺陷的淋巴瘤模型中均存在。Elimusertib与copanlisib联用在体外和体内均具有抗肿瘤活性,为淋巴瘤患者提供了潜在的新治疗选择。

要点

  • Elimusertib在多种淋巴瘤亚型中表现出强效抗肿瘤活性,与复制应激、细胞周期调控基因表达及CDKN2A缺失相关。
  • 在多个肿瘤模型中,elimusertib的抗肿瘤活性强于另一种ATR抑制剂ceralasertib,且在DDR功能正常和缺陷的淋巴瘤模型中均存在。
  • Elimusertib与copanlisib联用在体外和体内均具有抗肿瘤活性,为淋巴瘤患者提供了潜在的新治疗选择。

核心结论

  • Elimusertib在多种淋巴瘤亚型中表现出强效抗肿瘤活性,并与copanlisib联用在体外和体内均具有抗肿瘤活性,为淋巴瘤患者提供了潜在的新治疗选择。

研究设计与样本

  • 研究在大量淋巴瘤细胞系中表征ATR抑制剂elimusertib(BAY 1895344)的活性,并在体外和体内评估其与PI3K抑制剂copanlisib联用的效果。

主要发现

  • Elimusertib在多种淋巴瘤亚型中表现出强效抗肿瘤活性,与复制应激、细胞周期调控相关基因表达及CDKN2A缺失相关,CRISPR Cas9实验亦支持CDKN2A缺失的关联。
  • 在多个肿瘤模型中,elimusertib表现出广泛的抗肿瘤活性,强于另一种ATR抑制剂ceralasertib,且在DDR功能正常和缺陷的淋巴瘤模型中均存在该活性。
  • Elimusertib与copanlisib联用在体外和体内均具有抗肿瘤活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The DNA damage response (DDR) is the cellular process of preserving an intact genome and is often deregulated in lymphoma cells. The ataxia telangiectasia and Rad3-related (ATR) kinase is a crucial factor of DDR in the response to DNA single-strand breaks. ATR inhibitors are agents that have shown considerable clinical potential in this context. We characterized the activity of the ATR inhibitor elimusertib (BAY 1895344) in a large panel of lymphoma cell lines. Furthermore, we evaluated its activity combined with the clinically approved PI3K inhibitor copanlisib in vitro and in vivo. Elimusertib exhibits potent anti-tumour activity across various lymphoma subtypes, which is associated with the expression of genes related to replication stress, cell cycle regulation and, as also sustained by CRISPR Cas9 experiments, CDKN2A loss. In several tumour models, elimusertib demonstrated widespread anti-tumour activity stronger than ceralasertib, another ATR inhibitor. This activity is present in both DDR-proficient and DDR-deficient lymphoma models. Furthermore, a combination of ATR and PI3K inhibition by treatment with elimusertib and copanlisib has in vitro and in vivo anti-tumour activity, providing a potential new treatment option for lymphoma patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sartori G, Tarantelli C, Spriano F, et al. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib. Br J Haematol. 2023. PMID: 38011941. doi:10.1111/bjh.19218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。